SCHEMBL17538636

SCHEMBL17538636

O=C(CSc1nc2ccc(Cl)cc2[nH]1)Nc1ccc(Cl)cc1

nearest known ligand 0.78

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.75
▸ KMT2A Q03164 4/20 0.75
▸ MEN1 O00255 2/20 0.75
▸ ALDH1A1 P00352 2/20 0.75
▸ RAB9A P51151 1/20 0.69
▸ HSD17B10 Q99714 1/20 0.69
▸ LMNA P02545 3/20 0.69
▸ RECQL P46063 1/20 0.69
▸ NPSR1 Q6W5P4 1/20 0.68
▸ FPR2 P25090 3/20 0.67
▸ FPR1 P21462 1/20 0.67
▸ POLB P06746 2/20 0.65
▸ PRMT5 O14744 2/20 0.64
▸ WDR77 Q9BQA1 2/20 0.64
▸ THRB P10828 1/20 0.62
▸ ENPP1 P22413 1/20 0.61
▸ MPO P05164 1/20 0.61
▸ TSHR P16473 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16208438 0.91 MAPT (0.64) MAPTKMT2AMEN1ALDH1A1RAB9A
SCHEMBL16208343 0.90 THRB (0.78) MAPTKMT2AMEN1ALDH1A1RAB9A
SCHEMBL16208374 0.90 MAPT (0.84) MAPTKMT2AMEN1ALDH1A1LMNA
SCHEMBL16208395 0.89 THRB (0.79) MAPTKMT2AMEN1ALDH1A1RAB9A
SCHEMBL12487210 0.88 MPO (0.78) MAPTKMT2AMEN1ALDH1A1RAB9A
SCHEMBL12487161 0.87 KCNH2 (0.75) MAPTKMT2AMEN1ALDH1A1LMNA
SCHEMBL16208348 0.86 MAPT (0.59) MAPTKMT2AMEN1ALDH1A1RAB9A
SCHEMBL16208421 0.85 FPR2 (0.69) MAPTKMT2AMEN1ALDH1A1LMNA
SCHEMBL16208340 0.85 MAPT (0.66) MAPTKMT2AMEN1ALDH1A1RAB9A
SCHEMBL17531772 0.85 ENPP1 (0.68) MAPTKMT2AMEN1ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9643933-B2 Compounds useful as antibiotic tolerance inhibitors THE GENERAL HOSPITAL CORPORATION (US) 2017-05-09 — — US disclosed
US-20160052890-A1 COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS THE GENERAL HOSPITAL CORPORATION (US) 2016-02-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160052890-A1 COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS CFTR, SLC11A2, MRPS18A MAPT 4629/4885KMT2A 1369/4885MEN1 3997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback